RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
La Jolla Pharmaceutical Stock

La Jolla Pharmaceutical P/E 2024

La Jolla Pharmaceutical P/E

17.35

Ticker

LJPC

ISIN

US5034596040

WKN

A1XB6B

As of Oct 24, 2024, La Jolla Pharmaceutical's P/E ratio was 17.35, a 0% change from the 0 P/E ratio recorded in the previous year.

The La Jolla Pharmaceutical P/E history

La Jolla Pharmaceutical Aktienanalyse

What does La Jolla Pharmaceutical do?

La Jolla Pharmaceutical Co is a biopharmaceutical company specializing in the development and marketing of medicines for the treatment of rare and severe diseases. It was founded in 1989 in San Diego, California, by physician and scientist Ivor Royston. The company's business model is focused on researching, developing, and marketing drugs for patients with rare or severe diseases. The company prioritizes the needs and requirements of patients and aims to tailor each medication to maximize effectiveness. La Jolla's main focus is on researching medications for severe and rare diseases such as sepsis, acute kidney failure, and lung inflammation. These medications are intended to help patients who have limited or no treatment options. The company's portfolio includes various drugs, with antibodies being an important component for the treatment of inflammation and autoimmune diseases. Notably, Giapreza is one of the company's well-known medications approved by the FDA in December 2017, designed to treat adult patients with severe or most severe septic shock by increasing blood pressure. LJPC-401 is another significant medication developed by La Jolla Pharmaceutical Co, intended for the treatment of lupus nephritis, an autoimmune-related kidney inflammation that affects about 50% of systemic lupus erythematosus (SLE) patients. The company is also working on the development of a medication for migraine treatment, aiming to reduce the severity and frequency of migraine attacks. Overall, La Jolla Pharmaceutical Co has made significant progress in expanding its research activities and is committed to developing innovative medications to improve the lives of patients with rare and severe diseases. The company's focus on patient needs has proven to be a strategic advantage, positioning it competitively for the future. La Jolla Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering La Jolla Pharmaceutical's P/E Ratio

The Price to Earnings (P/E) Ratio of La Jolla Pharmaceutical is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing La Jolla Pharmaceutical's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of La Jolla Pharmaceutical is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in La Jolla Pharmaceutical’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about La Jolla Pharmaceutical stock

What is the price-to-earnings ratio of La Jolla Pharmaceutical?

The price-earnings ratio of La Jolla Pharmaceutical is currently 17.35.

How has the price-earnings ratio of La Jolla Pharmaceutical changed compared to last year?

The price-to-earnings ratio of La Jolla Pharmaceutical has increased by 0% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of La Jolla Pharmaceutical high compared to other companies?

Yes, the price-to-earnings ratio of La Jolla Pharmaceutical is high compared to other companies.

How does an increase in the price-earnings ratio of La Jolla Pharmaceutical affect the company?

An increase in the price-earnings ratio of La Jolla Pharmaceutical would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of La Jolla Pharmaceutical affect the company?

A decrease in the price-earnings ratio of La Jolla Pharmaceutical would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of La Jolla Pharmaceutical?

Some factors that influence the price-earnings ratio of La Jolla Pharmaceutical are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does La Jolla Pharmaceutical pay?

Over the past 12 months, La Jolla Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, La Jolla Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of La Jolla Pharmaceutical?

The current dividend yield of La Jolla Pharmaceutical is .

When does La Jolla Pharmaceutical pay dividends?

La Jolla Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of La Jolla Pharmaceutical?

La Jolla Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of La Jolla Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is La Jolla Pharmaceutical located?

La Jolla Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von La Jolla Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of La Jolla Pharmaceutical from 10/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/24/2024.

When did La Jolla Pharmaceutical pay the last dividend?

The last dividend was paid out on 10/24/2024.

What was the dividend of La Jolla Pharmaceutical in the year 2023?

In the year 2023, La Jolla Pharmaceutical distributed 0 USD as dividends.

In which currency does La Jolla Pharmaceutical pay out the dividend?

The dividends of La Jolla Pharmaceutical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The La Jolla Pharmaceutical stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von La Jolla Pharmaceutical

Our stock analysis for La Jolla Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of La Jolla Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.